Sci PharmtechTPE:4119 -0.34%67 Net Margin % is 10.93% as of Dec. 2025, which is 51% below its 10-year median of 22.48. GuruFocus rates TPE:4119 with a GF Score™ of 67/100 and a GF Value™ of NT$96.43 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 956 Drug Manufacturers companies, Sci Pharmtech ranks better than 57.95% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Sci Pharmtech's Net Income for the
three
months ended in Dec. 2025 was NT$39 Mil. Sci Pharmtech's Revenue for the
three
months ended in Dec. 2025 was NT$355 Mil. Therefore, Sci Pharmtech's net margin for the quarter that ended in Dec. 2025 was 10.93%.
The historical rank and industry rank for Sci Pharmtech's Net Margin % or its related term are showing as below:
TPE:4119'
s Net Margin % Range Over the Past 10 Years
Min: 6.44 Med: 22.48 Max: 35.09
Current: 7.99
TPE:4119's Net Margin % is ranked better than 57.95% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs TPE:4119: 7.99
Sci Pharmtech (TPE:4119) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sci Pharmtech Net Margin % Related Terms
Sci Pharmtech Net Margin % Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a Net Margin % of 10.93% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Sci Pharmtech and its competitors. This is 51% below median its historical median of 22.48. Over the past decade, Sci Pharmtech's Net Margin % has ranged from 6.44 to 35.09. According to the industry distribution chart, Sci Pharmtech ranks #402 out of 956 companies in the Drug Manufacturers industry, placing it in the top 42.1%.
Is Sci Pharmtech's Net Margin % too high?
Sci Pharmtech's current Net Margin % of 10.93% is 51% below median its 10-year median of 22.48. Over the past 10 years, this metric has ranged from a low of 6.44 to a high of 35.09. The Drug Manufacturers industry median Net Margin % is 5.56. Sci Pharmtech's value of 10.93% is 96.6% above this industry median. Based on the distribution chart, Sci Pharmtech ranks #402 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #402 out of 956 companies for Net Margin %. This puts Sci Pharmtech in the upper half of its industry. The industry median Net Margin % is 5.56. Sci Pharmtech's value of 10.93% is 96.6% above this benchmark. Historically, Sci Pharmtech's own Net Margin % has ranged from 6.44 to 35.09 over the past decade. While the company's 10-year median is 22.48 vs. the industry median of 5.56, Sci Pharmtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current Net Margin % of 10.93% is 96.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current Net Margin % is 10.93%, which is 51% below median its own 10-year median of 22.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.43, compared to a current price of NT$44.50 — trading 53.9% below its estimated fair value. The current Net Margin % is 10.93%, which is 51% below median its 10-year median of 22.48 and 96.6% above the Drug Manufacturers industry median of 5.56. Sci Pharmtech's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Net Margin % is 10.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$44.50 is trading 53.9% below its estimated GF Value™ of NT$96.43.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
Net Margin %: 10.93% (51% below median its 10-year median of 22.48)
GF Value™: NT$96.43 vs. price of NT$44.50 (53.9% below fair value)
Industry Position: 96.6% above the Drug Manufacturers median (#402 of 956)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score
Get the complete analysis for TPE:4119
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
